Qiagen N.V. revenue by segment QGEN
Qiagen N.V. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Diagnostic Solutions at $803.1 million, 38% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,090
|
1,978
|
1,965
|
2,142
|
2,252
|
1,870
|
1,526
|
1,502
|
1,418
|
1,338
|
| Diagnostic Solutions |
803
+7.2%
share 38.4%
|
749
+7.3%
share 37.9%
|
698
+5.6%
share 35.5%
|
661
+3.5%
share 30.9%
|
639
+38.6%
share 28.4%
|
461
-1.0%
share 24.6%
|
466
share 30.5%
|
—
|
—
|
—
|
| Sample Technologies |
661
+3.0%
share 31.6%
|
642
-3.2%
share 32.5%
|
663
-16.8%
share 33.7%
|
797
-6.3%
share 37.2%
|
851
+5.8%
share 37.8%
|
804
+46.6%
share 43.0%
|
548
share 35.9%
|
—
|
—
|
—
|
| PCR Nucleic Acid Amplification |
309
+2.8%
share 14.8%
|
300
+0.1%
share 15.2%
|
300
-23.2%
share 15.3%
|
391
-9.9%
share 18.2%
|
434
+19.4%
share 19.3%
|
364
+61.8%
share 19.4%
|
225
share 14.7%
|
—
|
—
|
—
|
| Genomics NGS |
242
+3.5%
share 11.6%
|
234
-2.2%
share 11.8%
|
239
+6.3%
share 12.2%
|
225
-8.3%
share 10.5%
|
245
+48.0%
share 10.9%
|
166
-9.9%
share 8.9%
|
184
share 12.0%
|
—
|
—
|
—
|
| Product And Service Other |
75
+40.7%
share 3.6%
|
53
-18.8%
share 2.7%
|
66
-3.7%
share 3.3%
|
68
-18.2%
share 3.2%
|
83
+8.6%
share 3.7%
|
77
-26.4%
share 4.1%
|
104
share 6.8%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- QGEN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Pl Venlo
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1015820
- Former names
- QIAGEN NV (until Feb 14, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.